AbbVie (NYSE: ABBV), a United States-based biopharmaceutical company, announced on Tuesday that it has entered into an exclusive worldwide collaboration with an option to license agreement with US-based HotSpot Therapeutics, Inc., a biotechnology company, for HotSpot's discovery-stage IRF5 program to treat autoimmune diseases. IRF5, a transcription factor that acts as a key regulator of certain types of immune responses and its dysregulation, is strongly associated in various poorly treated autoimmune disorders.
According to the terms of the contract, HotSpot will receive an upfront cash payment of USD40m and is likely to be eligible to receive up to USD295m in option fees and research and development milestones, with potential for further commercial milestones and tiered royalties on global net sales. If AbbVie exercises its option to license, then it will conduct all future clinical development, manufacturing and commercialisation activities for the IRF5 inhibitor program. HotSpot will also have a one-time option to share in global R&D costs in exchange for increased royalty payments.
The financial advisor to HotSpot on this transaction is Aquilo Partners, LP.
Opsidio doses first subject in OpSCF Phase 2a clinical trial
OncoResponse commences first subject dosing in OR502 Phase one/two trial
Photocure's partner Asieris Pharmaceuticals advances Hexvix NDA in China
Eli Lilly to open Lilly Gateway Labs in San Diego in H1 2024
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
MedGenome names new Advisory Board chairman
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Fusion Antibodies signs OptiMAL collaboration agreement with US National Cancer Institute
GeNeuro completes recruitment for long-COVID trial, anticipates top-line results by June 2024